Robyn M. Barfield
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Robyn M. Barfield has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Penelope M. Drake
Catalent Pharma Solutions, 5959 Horton Street, Suite 400, Emeryville, California 94608, United States
30 shared publications - Ayodele O. Ogunkoya
Catalent Pharma Solutions, Emeryville, California
23 shared publications - Brian A. Mendelsohn
Discovery Biotherapeutics, Exelixis, Inc., Alameda, California
23 shared publications - Christine M. Janson
Discovery Biotherapeutics, Exelixis, Inc., Alameda, California
23 shared publications - Colin L. Hickle
Catalent Pharma Solutions, Emeryville, California
23 shared publications - Dominick Y. Yeo
Catalent Pharma Solutions, Emeryville, California
23 shared publications
Latest Publications
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Table S8 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
Table S8: Toxicity of XB010 (1, 6 and 25 mg/kg doses) in NHPs.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S8 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
Table S8: Toxicity of XB010 (1, 6 and 25 mg/kg doses) in NHPs.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
Figure S4: HIC analysis of XB010. The DAR was confirmed as 1.8, as measured using peak areas from HIC versus a reference standard.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
Figure S4: HIC analysis of XB010. The DAR was confirmed as 1.8, as measured using peak areas from HIC versus a reference standard.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
In vivo tumor growth inhibition in murine PDX models. Significant tumor reduction was observed following single-dose intravenous administration of XB010 (10 mg/kg) in murine PDX models of (A) SSCHN, (B), NSCLC, and (C) breast cancer.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
In vivo tumor growth inhibition in murine PDX models. Significant tumor reduction was observed following single-dose intravenous administration of XB010 (10 mg/kg) in murine PDX models of (A) SSCHN, (B), NSCLC, and (C) breast cancer.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
Figure S2: Antigen binding of EXMA-001 and EXMA-004. Oxidative stress testing of EXMA-001 and EXMA-004 showed no changes in antigen binding after treatment with hydrogen peroxide. By comparison, an oxidation event taking place in the complementarity-determining region of the antibody altered the binding of EXMA-005 to the target antigen, meaning that this candidate was not considered suitable for further development.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
Figure S2: Antigen binding of EXMA-001 and EXMA-004. Oxidative stress testing of EXMA-001 and EXMA-004 showed no changes in antigen binding after treatment with hydrogen peroxide. By comparison, an oxidation event taking place in the complementarity-determining region of the antibody altered the binding of EXMA-005 to the target antigen, meaning that this candidate was not considered suitable for further development.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
Figure S3: Structure of XB010. Chemical structure of the linker (RED-601) and monomethyl auristatin E payload, conjugated to the EXMA-001-ST monoclonal antibody using site-specific SMARTag technology.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
Figure S3: Structure of XB010. Chemical structure of the linker (RED-601) and monomethyl auristatin E payload, conjugated to the EXMA-001-ST monoclonal antibody using site-specific SMARTag technology.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
Table S5: Tumor growth inhibition, response rates, and survival following IV administration of XB010 alone or in combination with anti-PD1 (h5T4-MC38 model).
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
Table S5: Tumor growth inhibition, response rates, and survival following IV administration of XB010 alone or in combination with anti-PD1 (h5T4-MC38 model).
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Data from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
The oncofetal antigen 5T4 is expressed in many solid tumors, making it an attractive antitumor target. XB010 is a novel, 5T4-targeted, antibody–drug conjugate developed using the SMARTag platform to optimize tolerability. We describe the development, design, and preclinical characterization of XB010. In vitro and in vivo efficacy of XB010 was assessed in cell-derived xenograft breast cancer cell lines (MCF-7 and MDA-MB-468) and in patient-derived xenograft tumor models (squamous cell carcinoma of the head and neck, non–small cell lung cancer, and breast cancer). Additionally, the in vivo combinatorial efficacy of XB010 + anti–PD-1 antibody was assessed in an MC38-h5T4 syngeneic colon cancer xenograft model. The toxicity profile of XB010 was evaluated in both Sprague–Dawley rats and cynomolgus monkeys. XB010 demonstrated in vitro cytotoxic effects with sub-nanomolar potency in the MCF-7 and MDA-MB-468 breast cancer cell lines and in vivo tumor growth inhibition (80%–99%) compared with vehicle-treated animals in xenograft and patient-derived xenograft models at doses of 5 to 10 mg/kg XB010. In the syngeneic MC38-h5T4–expressing colon cancer xenograft model, XB010 + anti–PD-1 showed improved efficacy compared with either agent administered alone. XB010 safety assessments demonstrated tolerability of doses up to 60 mg/kg in rats and up to 25 mg/kg in nonhuman primates. XB010 is a novel anti-5T4 antibody–drug conjugate that exhibits potent antitumor activity, inhibiting cancer cell growth in vitro and tumor growth in various in vivo models, with an acceptable toxicity profile. These findings support the evaluation of XB010 in clinical studies.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
The oncofetal antigen 5T4 is expressed in many solid tumors, making it an attractive antitumor target. XB010 is a novel, 5T4-targeted, antibody–drug conjugate developed using the SMARTag platform to optimize tolerability. We describe the development, design, and preclinical characterization of XB010. In vitro and in vivo efficacy of XB010 was assessed in cell-derived xenograft breast cancer cell lines (MCF-7 and MDA-MB-468) and in patient-derived xenograft tumor models (squamous cell carcinoma of the head and neck, non–small cell lung cancer, and breast cancer). Additionally, the in vivo combinatorial efficacy of XB010 + anti–PD-1 antibody was assessed in an MC38-h5T4 syngeneic colon cancer xenograft model. The toxicity profile of XB010 was evaluated in both Sprague–Dawley rats and cynomolgus monkeys. XB010 demonstrated in vitro cytotoxic effects with sub-nanomolar potency in the MCF-7 and MDA-MB-468 breast cancer cell lines and in vivo tumor growth inhibition (80%–99%) compared with vehicle-treated animals in xenograft and patient-derived xenograft models at doses of 5 to 10 mg/kg XB010. In the syngeneic MC38-h5T4–expressing colon cancer xenograft model, XB010 + anti–PD-1 showed improved efficacy compared with either agent administered alone. XB010 safety assessments demonstrated tolerability of doses up to 60 mg/kg in rats and up to 25 mg/kg in nonhuman primates. XB010 is a novel anti-5T4 antibody–drug conjugate that exhibits potent antitumor activity, inhibiting cancer cell growth in vitro and tumor growth in various in vivo models, with an acceptable toxicity profile. These findings support the evaluation of XB010 in clinical studies.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
Table S2: Tumor growth inhibition, response rates, and survival following IV administration of XB010 and controls (single dose in MCF-7 xenograft model).
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
Table S2: Tumor growth inhibition, response rates, and survival following IV administration of XB010 and controls (single dose in MCF-7 xenograft model).
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
Figure S5: RP-HPLC analysis of XB010 following single and tandem enzymatic cleavage. Single and tandem enzymatic cleavage with β-glucuronidase and cathepsin B confirmed the release of unconjugated MMAE.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
Figure S5: RP-HPLC analysis of XB010 following single and tandem enzymatic cleavage. Single and tandem enzymatic cleavage with β-glucuronidase and cathepsin B confirmed the release of unconjugated MMAE.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
Mean TK parameters for XB010 administered following repeat-dose administration to NHPs on day 1 and day 22.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
Mean TK parameters for XB010 administered following repeat-dose administration to NHPs on day 1 and day 22.